Marc Rondy1, Nathalie El Omeiri2, Mark G Thompson3, Alain Levêque2, Alain Moren4, Sheena G Sullivan5. 1. Epiconcept, Paris, France; Univ. Bordeaux, ISPED, Inserm, Bordeaux Population Health Research Center, UMR 1219, Bordeaux F-33000, France. Electronic address: m.rondy@epiconcept.fr. 2. Université Libre de Bruxelles, School of Public Health, Brussels, Belgium. 3. US Centers for Disease Control and Prevention (CDC), Influenza Division, Atlanta, USA. 4. Epiconcept, Paris, France. 5. WHO Collaborating Centre for Reference and Research on Influenza, Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Abstract
OBJECTIVES: Summary evidence of influenza vaccine effectiveness (IVE) against hospitalized influenza is lacking. We conducted a meta-analysis of studies reporting IVE against laboratory-confirmed hospitalized influenza among adults. METHODS: We searched Pubmed (January 2009 to November 2016) for studies that used test-negative design (TND) to enrol patients hospitalized with influenza-associated conditions. Two independent authors selected relevant articles. We calculated pooled IVE against any and (sub)type specific influenza among all adults, and stratified by age group (18-64 and 65 years and above) using random-effects models. RESULTS: We identified 3411 publications and 30 met our inclusion criteria. Between 2010-11 and 2014-15, the pooled seasonal IVE was 41% (95%CI:34;48) for any influenza (51% (95%CI:44;58) among people aged 18-64y and 37% (95%CI:30;44) among ≥65 years). IVE was 48% (95%CI:37;59),37% (95%CI:24;50) and 38% (95%CI:23;53) against influenza A(H1N1)pdm09, A(H3N2) and B, respectively. Among persons aged ≥65 year, IVE against A(H3N2) was 43% (95%CI:33;53) in seasons when circulating and vaccine strains were antigenically similar and 14% (95%CI:-3;30) when A(H3N2) variant viruses predominated. CONCLUSIONS: Influenza vaccines provided moderate protection against influenza-associated hospitalizations among adults. They seemed to provide low protection among elderly in seasons where vaccine and circulating A(H3N2) strains were antigenically variant.
OBJECTIVES: Summary evidence of influenza vaccine effectiveness (IVE) against hospitalized influenza is lacking. We conducted a meta-analysis of studies reporting IVE against laboratory-confirmed hospitalized influenza among adults. METHODS: We searched Pubmed (January 2009 to November 2016) for studies that used test-negative design (TND) to enrol patients hospitalized with influenza-associated conditions. Two independent authors selected relevant articles. We calculated pooled IVE against any and (sub)type specific influenza among all adults, and stratified by age group (18-64 and 65 years and above) using random-effects models. RESULTS: We identified 3411 publications and 30 met our inclusion criteria. Between 2010-11 and 2014-15, the pooled seasonal IVE was 41% (95%CI:34;48) for any influenza (51% (95%CI:44;58) among people aged 18-64y and 37% (95%CI:30;44) among ≥65 years). IVE was 48% (95%CI:37;59),37% (95%CI:24;50) and 38% (95%CI:23;53) against influenza A(H1N1)pdm09, A(H3N2) and B, respectively. Among persons aged ≥65 year, IVE against A(H3N2) was 43% (95%CI:33;53) in seasons when circulating and vaccine strains were antigenically similar and 14% (95%CI:-3;30) when A(H3N2) variant viruses predominated. CONCLUSIONS:Influenza vaccines provided moderate protection against influenza-associated hospitalizations among adults. They seemed to provide low protection among elderly in seasons where vaccine and circulating A(H3N2) strains were antigenically variant.
Authors: J Puig-Barbera; A Mira-Iglesias; M Tortajada-Girbes; F X Lopez-Labrador; A Belenguer-Varea; M Carballido-Fernandez; E Carbonell-Franco; C Carratala-Munuera; R Limon-Ramirez; J Mollar-Maseres; M Del Carmen Otero-Reigada; G Schwarz-Chavarri; J Tuells; V Gil-Guillen Journal: Euro Surveill Date: 2015-02-26
Authors: Allen C Cheng; Dominic E Dwyer; Mark Holmes; Lois B Irving; Simon Ga Brown; Grant W Waterer; Tony M Korman; Cameron Hunter; Saliya Hewagama; Nadia D Friedman; Peter A Wark; Graham Simpson; John W Upham; Simon D Bowler; Sanjaya N Senenayake; Tom C Kotsimbos; Paul M Kelly Journal: Commun Dis Intell Q Rep Date: 2014-06-30
Authors: Jesús Castilla; Pere Godoy; Angela Domínguez; Iván Martínez-Baz; Jenaro Astray; Vicente Martín; Miguel Delgado-Rodríguez; Maretva Baricot; Nuria Soldevila; José María Mayoral; José María Quintana; Juan Carlos Galán; Ady Castro; Fernando González-Candelas; Olatz Garín; Marc Saez; Sonia Tamames; Tomás Pumarola Journal: Clin Infect Dis Date: 2013-03-26 Impact factor: 9.079
Authors: Mark G Thompson; Allison Naleway; Alicia M Fry; Sarah Ball; Sarah M Spencer; Sue Reynolds; Sam Bozeman; Min Levine; Jacqueline M Katz; Manjusha Gaglani Journal: Vaccine Date: 2016-02-10 Impact factor: 3.641
Authors: Ana Mosterín Höpping; Janet McElhaney; Judith M Fonville; Douglas C Powers; Walter E P Beyer; Derek J Smith Journal: Vaccine Date: 2015-12-05 Impact factor: 3.641
Authors: Melissa K Andrew; Susan K Bowles; Graham Pawelec; Laura Haynes; George A Kuchel; Shelly A McNeil; Janet E McElhaney Journal: Drugs Aging Date: 2019-01 Impact factor: 3.923
Authors: Thoa Thi Minh Nguyen; Kathryn E Lafond; Tung Xuan Nguyen; Phu Dac Tran; Hang Minh Nguyen; Van Thi Cam Ha; Thu Thi Do; Nga Thu Ha; Jane F Seward; Jeffrey W McFarland Journal: Vaccine Date: 2020-01-27 Impact factor: 3.641
Authors: Sarah A Nowak; Andrew M Parker; Courtney A Gidengil; Andrea S Richardson; Matthew M Walsh; David P Kennedy; Raffaele Vardavas Journal: Soc Sci Med Date: 2022-01-11 Impact factor: 4.634
Authors: Andrea S Gershon; Hannah Chung; Joan Porter; Michael A Campitelli; Sarah A Buchan; Kevin L Schwartz; Natasha S Crowcroft; Aaron Campigotto; Jonathan B Gubbay; Timothy Karnauchow; Kevin Katz; Allison J McGeer; J Dayre McNally; David C Richardson; Susan E Richardson; Laura C Rosella; Andrew E Simor; Marek Smieja; George Zahariadis; Jeffrey C Kwong Journal: J Infect Dis Date: 2020-01-01 Impact factor: 5.226
Authors: Benjamin J Cowling; Ranawaka A P M Perera; Sophie A Valkenburg; Nancy H L Leung; A Danielle Iuliano; Yat Hung Tam; Jennifer H F Wong; Vicky J Fang; Athena P Y Li; Hau Chi So; Dennis K M Ip; Eduardo Azziz-Baumgartner; Alicia M Fry; Min Z Levine; Shivaprakash Gangappa; Suryaprakash Sambhara; Ian G Barr; Danuta M Skowronski; J S Malik Peiris; Mark G Thompson Journal: Clin Infect Dis Date: 2020-10-23 Impact factor: 9.079
Authors: Yasser Taher Al Hassan; Eduardo L Fabella; Edric D Estrella; Hassan Abdulfatah Al Ramadan; Ahmed Mansour Al Rajeh; Fatimah Hassan Al Saleh Journal: Hum Vaccin Immunother Date: 2021-01-30 Impact factor: 3.452